ICON Public (NASDAQ:ICLR) Releases FY25 Earnings Guidance

ICON Public (NASDAQ:ICLR) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $13.00-15.00 for the period, compared to the consensus estimate of $14.86. The company issued revenue guidance of $8.05-8.65 billion, compared to the consensus revenue estimate of $8.50 billion. ICON Public also updated its FY 2024 guidance to 13.900-14.100 EPS.

ICON Public Stock Down 0.1 %

Shares of NASDAQ ICLR opened at $217.99 on Tuesday. The company’s 50 day moving average price is $211.31 and its 200-day moving average price is $270.81. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.34 and a current ratio of 1.34. ICON Public has a 52-week low of $183.38 and a 52-week high of $347.72. The company has a market capitalization of $17.98 billion, a P/E ratio of 24.30, a price-to-earnings-growth ratio of 1.54 and a beta of 1.20.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm had revenue of $2.03 billion for the quarter, compared to the consensus estimate of $2.13 billion. During the same period last year, the company posted $3.10 EPS. The business’s revenue was down 1.2% compared to the same quarter last year. Equities analysts forecast that ICON Public will post 13.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ICLR. Leerink Partnrs raised ICON Public to a “strong-buy” rating in a research note on Wednesday, September 18th. The Goldman Sachs Group cut their price target on ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a report on Friday, October 25th. TD Cowen lowered their price objective on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Citigroup reduced their price objective on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a report on Monday, January 6th. Finally, Royal Bank of Canada started coverage on shares of ICON Public in a report on Tuesday, January 7th. They issued an “outperform” rating and a $263.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $287.00.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.